Matches in SemOpenAlex for { <https://semopenalex.org/work/W4253268103> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4253268103 endingPage "4166" @default.
- W4253268103 startingPage "4166" @default.
- W4253268103 abstract "4166 Background: Management of pancreatic cancer is a daunting task. We studied 21 patients of locally advanced unresectable pancreatic cancer in a phase I/II trial; utilizing hyperfractionated RT of 1.10 Gy/ fraction to a total dose of 63.80 Gy. Paclitaxel was delivered concomitantly in escalating doses from 20 to 70 mg/m2 weekly for 6 cycles. The MTD was observed at 60 mg/m2. The regimen was well tolerated, only one patient developed duodenal stricture and bleeding (RTOG IV morbidity) at 70 mg/m2 (Dose limiting toxicity). (1) Of 17 assessable patients, stable disease was observed in 10, partial response in 3, complete response in 2 and progression in 2. The 1 and 2 year survival rate was 45% and 27% respectively. The median survival of patients receiving ≤ 40 mg/m2 was 8 months, while the median survival for those receiving ≥ 50 mg/m2 had not been reached. Methods: We are currently accruing patients for a phase II study; using IMRT hyperfractionated RT to 63.80 Gy concomitantly with weekly Paclitaxel 60mg/m2 and gemcytabine 75mg/m2 for 6 cycles. Patients who achieve complete or good partial responses are considered for surgical resection 6–8 weeks post-therapy. Results: Regimen is thus far well tolerated. No major treatment interruptions or peri-treatment grades III or IV morbidities were encountered. Conclusions: This is work in progress. The employment of hyperfractionated Radiation therapy allows escalation of radiation dose without major late tissue toxicities. IMRT is currently being utilized in the same study. The addition of Paclitaxel and gemcytabine seems to be tolerated. Accrual is in progress and further results will follow. (1) Ashamalla, H., Zaki,B., Mokhtar, B., et.al., Int J Radiat Oncol Biol Phys; 55: 679–687, 2003 No significant financial relationships to disclose." @default.
- W4253268103 created "2022-05-12" @default.
- W4253268103 creator A5026473253 @default.
- W4253268103 creator A5050124979 @default.
- W4253268103 creator A5058507007 @default.
- W4253268103 creator A5072889329 @default.
- W4253268103 creator A5076143600 @default.
- W4253268103 creator A5086638427 @default.
- W4253268103 date "2004-07-15" @default.
- W4253268103 modified "2023-09-27" @default.
- W4253268103 title "Hyperfractionated concomitant in-field boost with gemcytabine, paclitaxel followed by surgery in locally advanced pancreatic cancer" @default.
- W4253268103 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.4166" @default.
- W4253268103 hasPublicationYear "2004" @default.
- W4253268103 type Work @default.
- W4253268103 citedByCount "1" @default.
- W4253268103 crossrefType "journal-article" @default.
- W4253268103 hasAuthorship W4253268103A5026473253 @default.
- W4253268103 hasAuthorship W4253268103A5050124979 @default.
- W4253268103 hasAuthorship W4253268103A5058507007 @default.
- W4253268103 hasAuthorship W4253268103A5072889329 @default.
- W4253268103 hasAuthorship W4253268103A5076143600 @default.
- W4253268103 hasAuthorship W4253268103A5086638427 @default.
- W4253268103 hasConcept C121608353 @default.
- W4253268103 hasConcept C126322002 @default.
- W4253268103 hasConcept C126894567 @default.
- W4253268103 hasConcept C141071460 @default.
- W4253268103 hasConcept C155806632 @default.
- W4253268103 hasConcept C2776694085 @default.
- W4253268103 hasConcept C2777292972 @default.
- W4253268103 hasConcept C2779384505 @default.
- W4253268103 hasConcept C2780210213 @default.
- W4253268103 hasConcept C2781413609 @default.
- W4253268103 hasConcept C2908786992 @default.
- W4253268103 hasConcept C29730261 @default.
- W4253268103 hasConcept C2989005 @default.
- W4253268103 hasConcept C31760486 @default.
- W4253268103 hasConcept C509974204 @default.
- W4253268103 hasConcept C71924100 @default.
- W4253268103 hasConceptScore W4253268103C121608353 @default.
- W4253268103 hasConceptScore W4253268103C126322002 @default.
- W4253268103 hasConceptScore W4253268103C126894567 @default.
- W4253268103 hasConceptScore W4253268103C141071460 @default.
- W4253268103 hasConceptScore W4253268103C155806632 @default.
- W4253268103 hasConceptScore W4253268103C2776694085 @default.
- W4253268103 hasConceptScore W4253268103C2777292972 @default.
- W4253268103 hasConceptScore W4253268103C2779384505 @default.
- W4253268103 hasConceptScore W4253268103C2780210213 @default.
- W4253268103 hasConceptScore W4253268103C2781413609 @default.
- W4253268103 hasConceptScore W4253268103C2908786992 @default.
- W4253268103 hasConceptScore W4253268103C29730261 @default.
- W4253268103 hasConceptScore W4253268103C2989005 @default.
- W4253268103 hasConceptScore W4253268103C31760486 @default.
- W4253268103 hasConceptScore W4253268103C509974204 @default.
- W4253268103 hasConceptScore W4253268103C71924100 @default.
- W4253268103 hasIssue "14_suppl" @default.
- W4253268103 hasLocation W42532681031 @default.
- W4253268103 hasOpenAccess W4253268103 @default.
- W4253268103 hasPrimaryLocation W42532681031 @default.
- W4253268103 hasRelatedWork W1975164313 @default.
- W4253268103 hasRelatedWork W2009015878 @default.
- W4253268103 hasRelatedWork W2083542046 @default.
- W4253268103 hasRelatedWork W2087807168 @default.
- W4253268103 hasRelatedWork W2189014981 @default.
- W4253268103 hasRelatedWork W2349559277 @default.
- W4253268103 hasRelatedWork W2369999122 @default.
- W4253268103 hasRelatedWork W2376042985 @default.
- W4253268103 hasRelatedWork W2531883845 @default.
- W4253268103 hasRelatedWork W648802693 @default.
- W4253268103 hasVolume "22" @default.
- W4253268103 isParatext "false" @default.
- W4253268103 isRetracted "false" @default.
- W4253268103 workType "article" @default.